Recruiting PHASE1 INTERVENTIONAL 2-arm NCT07053917

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM)

Sponsor: Johns Hopkins University

Conditions Chronic Stroke Hemiparesis After Stroke Hemiplegia Following Ischemic Stroke Hemiplegia and Hemiparesis Hemiplegia and/or Hemiparesis Following Stroke Intracerebral Haemorrhage Intracerebral Haemorrhage (ICH) Intracerebral Hemorrhage Basal Ganglia Ischemic Stroke Ischemic Stroke and Hemorrhagic Stroke Middle Cerebral Artery Stroke Stroke

Interventions Psilocybin (Usona Institute)

Updated 4 times since 2025 Last updated: Feb 11, 2026 Started: Feb 9, 2026 Primary completion: Feb 28, 2027 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07053917, this PHASE1 trial focuses on Chronic Stroke and Hemiparesis After Stroke and remains actively recruiting participants. Sponsored by Johns Hopkins University, it has been updated 4 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Dec 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE1
Oct 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE1
Aug 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johns Hopkins University
Rose Hill
University of California, Berkeley
Usona Institute

Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States